Canagliflozin, an SGLT2 inhibitor, corrects glycemic...

  • Main
  • 2020 / 9
  • Canagliflozin, an SGLT2 inhibitor, corrects glycemic...
Bone 2020 / 9

Canagliflozin, an SGLT2 inhibitor, corrects glycemic dysregulation in TallyHO model of T2D but only partially prevents bone deficits

Thrailkill, Kathryn M., Bunn, R. Clay, Uppuganti, Sasidhar, Ray, Philip, Popescu, Iuliana, Kalaitzoglou, Evangelia, Fowlkes, John L., Nyman, Jeffry S.
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Journal:
Bone
DOI:
10.1016/j.bone.2020.115625
Date:
September, 2020
File:
PDF, 3.24 MB
2020
Conversion to is in progress
Conversion to is failed